

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/781,695	02/12/2001	Terrence L. Graham	22727/04056	6144
24024 7	7590 02/10/2003			
CALFEE HALTER & GRISWOLD, LLP 800 SUPERIOR AVENUE SUITE 1400			EXAMINER	
			PRYOR, ALTON NATHANIEL	
CLEVELAND, OH 44114			ART UNIT	PAPER NUMBER
			1616	

DATE MAILED: 02/10/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. **09/781,695**

Applicant(s)

Gramham et al

Examiner

Alton Pryor

Art Unit **1616**

	this communication appears of	on the cover sheet with the correspondence address			
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.					
 Extensions of time may be available under mailing date of this communication. 	the provisions of 37 CFR 1.136 (a). In r	no event, however, may a reply be timely filed after SIX (6) MONTHS from the			
 If the period for reply specified above is les If NO period for reply is specified above, the Failure to reply within the set or extended 	ne maximum statutory period will apply ar period for reply will, by statute, cause the three months after the mailing date of th	e statutory minimum of thirty (30) days will be considered timely. nd will expire SIX (6) MONTHS from the mailing date of this communication. e application to become ABANDONED (35 U.S.C. § 133). nis communication, even if timely filed, may reduce any			
Status					
		002 .			
2a) This action is FINAL.	2b) <mark>X This acti</mark>	on is non-final.			
		xcept for formal matters, prosecution as to the merits is the Quayle, 1935 C.D. 11; 453 O.G. 213.			
Disposition of Claims					
4) 💢 Claim(s) <u>1-43</u>		is/are pending in the application.			
		is/are withdrawn from consideration.			
5)	· · · · · · · · · · · · · · · · · · ·	is/are allowed.			
6) X Claim(s) 1, 10-12, 14, 1	15, 17-21, and 23	is/are rejected.			
7) Claim(s)		is/are objected to.			
8)		are subject to restriction and/or election requirement.			
Application Papers					
9) \square The specification is obje	cted to by the Examiner.				
10) The drawing(s) filed on	is/are	a) \square accepted or b) \square objected to by the Examiner.			
Applicant may not reque	st that any objection to the dr	rawing(s) be held in abeyance. See 37 CFR 1.85(a).			
11) \square The proposed drawing of	correction filed on	is: a) \square approved b) \square disapproved by the Examiner.			
If approved, corrected di	rawings are required in reply to	o this Office action.			
12) The oath or declaration	is objected to by the Examir	ner.			
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) All b) Some* c) None of:					
1. Certified copies of	the priority documents have	e been received.			
2. Certified copies of	the priority documents have	e been received in Application No			
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).					
		e certified copies not received.			
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).					
a) The translation of the foreign language provisional application has been received.					
15) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
1) Notice of References Cited (PTO-892)		4) Interview Summary (PTO-413) Paper No(s).			
2) Notice of Draftsperson's Patent Drawin		5) Notice of Informal Patent Application (PTO-152)			
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)					

Application/Control Number: 09781695

Art Unit:

Duplicate Claim Warning

Applicant is advised that should claim 1 be found allowable, claim 10 will be objected to under 37 CAR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 706.03(k).

Claim Rejection under 35 U.S.C. 112, 2nd paragraph

1. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

2. Claims 1,10-12,14,15,17-21,23 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1,10-12,14,15,17-21,23 are rejected for not reciting that R10 in claims 1 and 12 can be a substituted aromatic as required by the election of clofibric acid.

Claim Rejection under 35 U.S.C. 102(b)

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Application/Control Number: 09781695

Art Unit:

4. Claims 1,10,11,15,17,21 are rejected under 35 U.S.C. 102(b) as being anticipated by Long et al (Plant Physiology, 1973, vol. 51(1), pp. 128-35). Long teaches the injection of a composition comprising clofibric acid into the stem of a bean plant. Long also teaches that the composition being injected comprises 2,4,5-T. 2,4,5-T is an additional compound present in the clofibric acid composition of the prior art. The presence of 2,4,5-T meets the limitation of claim 21. Claim 21 teaches a composition comprising an additional component functioning to enhance the release of isoflavones from conjugate sugar and / or to enhance the incorporation of aglycones into glyceollin. However, it is important to note that in a claim to a composition or compound a statement to the intended use of the composition or compound has no patentable significance.

Therefore, Long meets the limitation of claim 21 with the compound 2,4,5-T since claim 21 part (b) does not specify particular compounds. Although the prior art does not state that injection of the clofibric composition into the bean stem induces production of isoflavones in a plant, it is inherent that said induction will occur since Long teaches the injection of a clofibric acid composition into bean plant stem. See abstract.

Election

The Election of clofibric acid is not allowable as indicated in above 35 U.S.C. 112, 2nd paragraph and 35 U.S.C. 102(b) rejections above.

Art Unit:

Telephonic Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alton Pryor whose telephone number is (703) 308-4691. The examiner can normally be reached on Monday through Friday from 8:00 a.m. to 4:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jose Dees, can be reached on (703) 308-4628. The fax phone number for this Group is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

ALTON N. PRYOR
Alton Pryor PRIMARY EXAMINER

Primary Examiner, AU 1616

2/5/03